within Pharmacolibrary.Drugs.ATC.L;

model L04AF03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.79,
    Cl             = 0.0003916666666666667,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.294,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.021666666666666667,
    Tlag           = 18.0,            
    Vdp             = 0.234,
    k12             = 53.2,
    k21             = 53.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AF03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and other inflammatory disorders. It is approved for use in several countries including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration in adult healthy subjects; population PK based on phase I and phase III studies.</p><h4>References</h4><ol><li><p>Faggiani, I, et al., &amp; Danese, S (2024). Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn&#x27;s disease. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(5) 297–305. DOI:<a href=\"https://doi.org/10.1080/17425255.2024.2349711\">10.1080/17425255.2024.2349711</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38712496/\">https://pubmed.ncbi.nlm.nih.gov/38712496</a></p></li><li><p>Sandborn, WJ, et al., &amp; Panes, J (2020). Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn&#x27;s Disease. <i>Gastroenterology</i> 158(8) 2123–2138.e8. DOI:<a href=\"https://doi.org/10.1053/j.gastro.2020.01.047\">10.1053/j.gastro.2020.01.047</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32044319/\">https://pubmed.ncbi.nlm.nih.gov/32044319</a></p></li><li><p>Sandborn, WJ, et al., &amp; Higgins, PDR (2020). Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. <i>Gastroenterology</i> 158(8) 2139–2149.e14. DOI:<a href=\"https://doi.org/10.1053/j.gastro.2020.02.030\">10.1053/j.gastro.2020.02.030</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32092309/\">https://pubmed.ncbi.nlm.nih.gov/32092309</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AF03;
